Documents detail complaints that FDA managers are too lenient with industry

Internal Food and Drug Administration documents indicate that an FDA official overruled agency scientists and approved the sale of an imaging device for breast cancer after receiving a phone call from a Connecticut congressman. The legislator’s call and its effect on what is supposed to be a science-based approval process is only one of many of accusations in documents obtained by The New York Times regarding disputes within the Food and Drug Administration's office of device evaluation.